Newbury Pharmaceuticals AB (publ) (NEWBRY.ST)

SEK 3.42

(-2.29%)

Revenue Summary of Newbury Pharmaceuticals AB (publ)

  • Newbury Pharmaceuticals AB (publ)'s latest annual revenue in 2024 was 36.82 Million SEK , up 258.75% from previous year.
  • Newbury Pharmaceuticals AB (publ)'s latest quarterly revenue in 2024 Q4 was 21.12 Million SEK , up 1424.03% from previous quarter.
  • Newbury Pharmaceuticals AB (publ) reported a annual revenue of 10.26 Million SEK in annual revenue 2023, up 86.11% from previous year.
  • Newbury Pharmaceuticals AB (publ) reported a annual revenue of 5.51 Million SEK in annual revenue 2022, up 94.98% from previous year.
  • Newbury Pharmaceuticals AB (publ) reported a quarterly revenue of 11.18 Million SEK for 2024 Q1, up 295.65% from previous quarter.
  • Newbury Pharmaceuticals AB (publ) reported a quarterly revenue of 21.12 Million SEK for 2024 Q4, up 1424.03% from previous quarter.

Annual Revenue Chart of Newbury Pharmaceuticals AB (publ) (2024 - 2021)

Historical Annual Revenue of Newbury Pharmaceuticals AB (publ) (2024 - 2021)

Year Revenue Revenue Growth
2024 36.82 Million SEK 258.75%
2023 10.26 Million SEK 86.11%
2022 5.51 Million SEK 94.98%
2021 2.82 Million SEK 0.0%

Peer Revenue Comparison of Newbury Pharmaceuticals AB (publ)

Name Revenue Revenue Difference
AcuCort AB - SEK -Infinity%
AlzeCure Pharma AB (publ) - SEK -Infinity%
BioGaia AB (publ) 1.29 Billion SEK 97.159%
Enzymatica AB (publ) 50.9 Million SEK 27.65%
Enorama Pharma AB (publ) 1.35 Million SEK -2612.003%
Gabather AB (publ) - SEK -Infinity%
Klaria Pharma Holding AB (publ.) - SEK -Infinity%
Moberg Pharma AB (publ) - SEK -Infinity%
Nanexa AB (publ) 29.32 Million SEK -25.581%
ODI Pharma AB 22.44 Million SEK -64.07%
Orexo AB (publ) 638.8 Million SEK 94.235%
Probi AB (publ) 627.68 Million SEK 94.133%
Swedencare AB (publ) 2.32 Billion SEK 98.416%
Swedish Orphan Biovitrum AB (publ) 22.12 Billion SEK 99.834%
Toleranzia AB 50.92 Million SEK 27.673%
Vivesto AB 1.01 Million SEK -3528.473%